Presentation by Dr. ruben mesa for those with MF interested in the recently FDA approved pacritinib.
Top 10 Facts that Patients with Myeloproliferati... - MPN Voice
Top 10 Facts that Patients with Myeloproliferative Neoplasms Need to Know About Pacritinib (Vonjo)
Written by
hunter5582
To view profiles and participate in discussions please or .
4 Replies
•
Thankyou for the links to various discussions . It really helps to have an overview of the current treatment landscape this way . The link to the previous MPN progression webinar was also very good . One takeaway that called out to me was that - it is of value to do a regular genetic profiling for mutations and allele burden . It was actually after reading your thoughts that I got a myeloid profile done for myself . I now have a ball -park allele burden to start with .
I learn much from your crisp commentary on your own treatment path as well . Thankyou again .
How did you arrange the myeloid profile for yourself? Are you in the UK?
No I do not live in the UK but in India currently.Though it is not the easiest to get it done here, yet there are a few labs which do these tests.
A few takeaways as I understand it:
-Pacritinib (Vonjo) does not inhibit JAk1 to the extent that prior Jak inhibitors do. (Rux, Fedr) Less Jak1 inhibiting allows platelets to stay higher. This is esp useful for MF patients with PLT less than 50 x 10-9. (Cytopenic MF) This slide shows that the low PLT MF did not have an approved treatment option. With Vonjo there is an option.
-Vonjo also uniquely inhibits IRAK1. This can improve inflammation and may help with fibrosis.
-The PERSIST trials by Dr Mesa were the 1st to include those with <50 PLT counts.
-Better spleen size than Rux.
-PLT can actually improve under Vonjo.
-AE includes GI issues, but tends to decrease with time.
-Vonjo likely to be 1st line for the lower PLT patients.
-Don't switch if your current therapy is working
-Vonjo is not approved for PV nor ET, but that could change.
Pacritinib vs Rux etc
